Revenue Insights: Bristol-Myers Squibb Company and Regeneron Pharmaceuticals, Inc. Performance Compared

Pharma Giants' Revenue Growth: A Decade of Transformation

__timestampBristol-Myers Squibb CompanyRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 2014158790000002819557000
Thursday, January 1, 2015165600000004103728000
Friday, January 1, 2016194270000004860427000
Sunday, January 1, 2017207760000005872227000
Monday, January 1, 2018225610000006710800000
Tuesday, January 1, 2019261450000007863400000
Wednesday, January 1, 2020425180000008497100000
Friday, January 1, 20214638500000016071700000
Saturday, January 1, 20224615900000012172900000
Sunday, January 1, 20234500600000013117200000
Monday, January 1, 20244830000000014202000000
Loading chart...

Unveiling the hidden dimensions of data

Revenue Growth: A Tale of Two Pharmaceutical Giants

In the competitive landscape of the pharmaceutical industry, Bristol-Myers Squibb Company and Regeneron Pharmaceuticals, Inc. have showcased remarkable revenue trajectories over the past decade. Since 2014, Bristol-Myers Squibb has seen its revenue more than double, peaking in 2021 with a staggering 192% increase from its 2014 figures. This growth is largely attributed to strategic acquisitions and a robust pipeline of innovative therapies.

On the other hand, Regeneron Pharmaceuticals has demonstrated a consistent upward trend, with its revenue growing by approximately 465% from 2014 to 2021. This impressive growth is driven by the success of its flagship products and a strong focus on research and development.

While both companies have experienced fluctuations, their ability to adapt and innovate in a rapidly changing market underscores their resilience and commitment to advancing healthcare solutions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025